Watchman Device Efficacy in Patients with Reduced Left Ventricular Ejection Fraction

Introduction to Watchman Device Efficacy

The Watchman device can be effective for stroke prevention in atrial fibrillation patients with reduced left ventricular ejection fraction, but oral anticoagulation remains the preferred first-line therapy unless absolute contraindications exist, according to the American College of Cardiology 1

The Watchman device has demonstrated non-inferiority to warfarin for stroke prevention in atrial fibrillation patients, with specific benefits in reducing hemorrhagic stroke and cardiovascular death, as reported by the European Society of Cardiology 2, 3
A patient-level meta-analysis confirmed comparable rates of the composite primary efficacy outcome with significantly lower hemorrhagic stroke and cardiovascular death compared to warfarin, as stated by the American Heart Association 2, 1

The European Society of Cardiology recommends percutaneous left atrial appendage occlusion may be considered (Class IIb) only in patients with atrial fibrillation and contraindications for long-term anticoagulant treatment, with a weak recommendation and the device positioned as a second-line option 6, 1
The American College of Cardiology/American Heart Association/Heart Rhythm Society similarly recommends percutaneous left atrial appendage occlusion may be considered in patients with atrial fibrillation at increased risk of stroke who have contraindications to long-term anticoagulation (Class IIb, Level of Evidence B-NR) 1

Patients with reduced left ventricular ejection fraction require careful hemodynamic monitoring during any cardiovascular intervention, as emphasized by the American College of Cardiology 7
The procedural risks of Watchman implantation include serious periprocedural complications in approximately 6-7% of cases, including pericardial effusion requiring drainage, device embolization, and major bleeding, as reported by the European Society of Cardiology 1

For atrial fibrillation patients with reduced left ventricular ejection fraction, first-line treatment is oral anticoagulation (direct oral anticoagulant preferred, or warfarin INR 2.0-3.0) unless absolute contraindications exist, as recommended by the American Heart Association 4, 5, 1
The Watchman device may be considered only if the patient has absolute contraindications to all oral anticoagulants and can tolerate at least 45 days of post-procedural anticoagulation, as stated by the European Society of Cardiology 3, 1

Mandatory surveillance after Watchman implantation includes transesophageal echocardiography at 45 days and 1 year to evaluate for device-related thrombus and peridevice leak before discontinuing anticoagulation, as recommended by the American College of Cardiology 8
Any peridevice leak detected by transesophageal echocardiography is associated with increased thromboembolism risk, as reported by the European Society of Cardiology 8
Deep device implantation (>10 mm from pulmonary vein limbus) increases device-related thrombus risk, as stated by the American Heart Association 8